Senseonics Holdings, a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitor (CGM) systems for people with diabetes, in partnership with our global commercial partner, Ascensia Diabetes Care, and St. Louis-based Mercy, a leading health care system and accountable care organization, announced a first-of-its-kind relationship in a diabetes population management program.
The collaboration marks the first time Senseonics’ Eversense CGM technology will be used across a health system and the first implementation of Senseonics’ new Eversense Remote Patient Monitoring (RPM) solution to drive significant advancement in diabetes management for patients.
“There are many barriers patients with diabetes struggle with and glucose monitoring is at the top,” said Dr. Jeff Ciaramita, President, Mercy specialty service lines. “We believe the launch of the Eversense Remote Patient Monitoring program will transform diabetes care for our patients and providers. This program is designed to enhance our ability to monitor patient health remotely and support timely interventions that can significantly improve our patients’ lives and reduce costly, avoidable hospitalizations.”
Mercy has more than a decade of experience with remote patient monitoring for a variety of conditions. With more than 3 million patients served annually, it is expected that approximately 30,000 Mercy patients could benefit from a CGM system. Providers at Mercy plan to begin placing new Eversense devices with patients this July. In a phased approach, Mercy will roll the program out first in its St. Louis-area communities followed by the remaining regions in Mercy’s system in Missouri, Kansas, Arkansas and Oklahoma throughout 2025.
“We plan to work with our physicians, from the Mercy proceduralists, who will perform insertions, to the primary care teams who monitor patients regularly and endocrinologists who support at-risk patients,” Dr. Ciaramita said. “The integration of the Eversense CGM+RPM solution is a representation of Mercy’s ongoing commitment to providing our patients proactive, predictive and personalized care.”
“Mercy is known as an innovative health care leader, so it makes sense that they are the first health system to work with us towards providing a comprehensive approach towards better diabetes care,” said Tim Goodnow, PhD, Senseonics president and chief executive officer. “Together with Mercy and Ascensia, we are building a forward-looking approach to provide access for diabetes patients, from identifying those in need to leveraging the latest continuous glucose monitoring technology and providing the support patients need to better self-manage their diabetes. Additionally, we plan to work with Mercy to provide patient access to our exciting future products, including the next-gen 365-day product we hope to bring to market later this year. Together, we are pushing the frontier of diabetes management.”
SOURCE: Businesswire